⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11640981 | 1.00 | — | — | |
| SCHEMBL15781544 | 1.00 | — | — | |
| SCHEMBL11640986 | 1.00 | — | — | |
| SCHEMBL64268 | 1.00 | — | — | |
| SCHEMBL1756079 | 1.00 | — | — | |
| SCHEMBL10980272 | 0.95 | — | — | |
| SCHEMBL22901407 | 0.95 | ALDH1A1 (0.36) | — | |
| SCHEMBL14674612 | 0.95 | — | — | |
| SCHEMBL14674108 | 0.95 | ALDH1A1 (0.36) | — | |
| SCHEMBL14674107 | 0.95 | ALDH1A1 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240216521-A1 | METHODS OF PREPARING CELL-BINDING AGENT-DRUG CONJUGATES | IMMUNOGEN INC (US) | 2024-07-04 | — | — | US | disclosed |
| US-20240216521-A1 | METHODS OF PREPARING CELL-BINDING AGENT-DRUG CONJUGATES | IMMUNOGEN INC (US) | 2024-07-04 | — | — | US | disclosed |
| US-11833214-B2 | Methods of preparing cell-binding agent-drug conjugates | IMMUNOGEN, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-11833214-B2 | Methods of preparing cell-binding agent-drug conjugates | IMMUNOGEN, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-20200405874-A1 | METHODS OF PREPARING CELL-BINDING AGENT-DRUG CONJUGATES | IMMUNOGEN, INC. | 2020-12-31 | — | — | US | disclosed |
| US-8507654-B2 | Altered antibodies | UCB PHARMA S.A. (BE) | 2013-08-13 | — | — | US | disclosed |
| US-8507654-B2 | Altered antibodies | UCB PHARMA S.A. (BE) | 2013-08-13 | — | — | US | disclosed |
| US-8378073-B2 | Process for attaching effector molecules to proteins | UCB PHARMA S.A. (BE) | 2013-02-19 | — | — | US | disclosed |
| US-8378073-B2 | Process for attaching effector molecules to proteins | UCB PHARMA S.A. (BE) | 2013-02-19 | — | — | US | disclosed |
| EP-2074143-B1 | ALTERED ANTIBODIES | UCB PHARMA SA (BE) | 2012-04-18 | — | — | EP | disclosed |
| EP-1912673-B1 | PROCESS FOR ATTACHING EFFECTOR MOLECULES TO PROTEINS | UCB PHARMA SA (BE) | 2011-03-23 | — | — | EP | disclosed |
| US-20100093977-A1 | Altered Antibodies | UCB PHARMA S.A. (BE) | 2010-04-15 | — | — | US | disclosed |
| US-20100093977-A1 | Altered Antibodies | UCB PHARMA S.A. (BE) | 2010-04-15 | — | — | US | disclosed |
| US-20080306246-A1 | Process for Attaching Effector Molecules to Proteins | UCB PHARMA S.A. (BE) | 2008-12-11 | — | — | US | disclosed |
| US-20080306246-A1 | Process for Attaching Effector Molecules to Proteins | UCB PHARMA S.A. (BE) | 2008-12-11 | — | — | US | disclosed |
| WO-2008038024-A1 | ALTERED ANTIBODIES | UCB PHARMA S.A. (BE) | 2008-04-03 | — | — | WO | disclosed |
| WO-2007003898-A1 | PROCESS FOR ATTACHING EFFECTOR MOLECULES TO PROTEINS | UCB PHARMA S.A. (BE) | 2007-01-11 | — | — | WO | disclosed |
| EP-0372870-A2 | Novel heterocyclic pesticidal compounds | ROUSSEL-UCLAF (FR) | 1990-06-13 | — | — | EP | disclosed |